What are Mission Vision & Core Values of Valneva Company?

Valneva Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

What are the Mission, Vision, and Core Values of Valneva?

Mission and vision statements are foundational cornerstones for any successful business, articulating its purpose, aspirations, and guiding principles. They are strategic blueprints influencing every aspect of a company's operations, from product development to market positioning and corporate culture. Valneva, a specialty vaccine company, operates at the forefront of global health.

Valneva is dedicated to developing, manufacturing, and commercializing prophylactic vaccines for infectious diseases with significant unmet medical needs. Their articulated principles ensure alignment across the organization, guiding their integrated expertise to bring innovative vaccine solutions to market and protect global populations. For example, in the first half of 2025, Valneva reported total revenues of €97.6 million, an increase of 37.8% compared to the first half of 2024, demonstrating their strategic focus. Learn more about their operational environment in the Valneva PESTEL Analysis.

Valneva's mission statement precisely defines its target customers as global populations susceptible to infectious diseases with limited or no existing preventive options. The company focuses on prophylactic vaccines, specifically specialty vaccines with significant public health impact. The market scope is global, aiming to provide access to its vaccines worldwide. Valneva's unique value proposition stems from its integrated expertise in vaccine development and manufacturing, striving to deliver first-, best-, or only-in-class vaccine solutions. This mission is strongly innovation-focused and patient-centric, reflecting Valneva company mission and goals.

Patient-Centric Innovation

Valneva prioritizes developing vaccines for diseases with high unmet medical needs, directly addressing global health challenges. This aligns with Valneva's core principles and values.

Global Accessibility

The company is committed to ensuring its vaccines reach populations worldwide, emphasizing equitable access. This commitment is a key aspect of Valneva's corporate purpose.

Integrated Expertise

Valneva leverages its comprehensive capabilities in vaccine development and manufacturing to create impactful solutions. This integrated approach supports Valneva's strategic priorities.

First-in-Class Solutions

A core objective is to deliver novel or superior vaccine candidates, setting new standards in preventive medicine. This highlights Valneva's vision for the future.

Research and Development Focus

Significant investment in R&D, such as the €62.8 million in 2024, drives the advancement of critical vaccine candidates. This demonstrates Valneva's core values explained through action.

Strategic Partnerships

Collaborations, like those for the chikungunya vaccine in India and Brazil by 2026, facilitate broader vaccine availability. This is part of Valneva's company culture and values.

Valneva's ongoing investment in research and development, totaling €62.8 million in 2024, directly reflects this mission, advancing vaccine candidates like VLA15 for Lyme disease and S4V2 for Shigella. Another example is their commitment to enable access to their single-shot chikungunya vaccine (IXCHIQ) in India and Brazil by 2026 through technology transfers and partnerships, showcasing Valneva mission vision and values. For more insights into the company's financial operations, consider reading about the Revenue Streams & Business Model of Valneva.

Valneva SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Valneva's vision is to achieve a world free from vaccine-preventable diseases, where no individual suffers or dies unnecessarily. This ambitious goal drives their focus on developing innovative vaccines. The company aims to make a significant global health impact by addressing unmet medical needs through scientific advancement and strategic partnerships, such as the collaboration with Pfizer on the Lyme disease vaccine candidate VLA15.

Valneva Mission

Valneva's mission is to provide innovative vaccines for infectious diseases with significant unmet medical needs. This involves leveraging their expertise in vaccine development and manufacturing.

Valneva Core Values

The company's core values include a commitment to innovation, scientific excellence, and patient focus. These principles guide their research and development efforts.

Strategic Priorities

Valneva's strategic priorities involve advancing their vaccine pipeline, expanding commercial reach, and maintaining financial discipline. This ensures sustainable growth and impact.

Company Culture

Valneva fosters a culture of collaboration, integrity, and accountability. This environment supports their mission and encourages employee engagement.

Global Impact

The company aims for global impact by developing vaccines that address widespread health challenges. Their efforts contribute to public health worldwide.

Research & Development

Valneva invests significantly in R&D, with a focus on novel vaccine candidates. This commitment drives their pipeline and future product offerings.

Valneva's vision is to contribute to a world in which no one dies or suffers from a vaccine-preventable disease. This future-oriented vision outlines a profound global impact, aspiring to eliminate preventable deaths and suffering caused by infectious diseases. While ambitious, it serves as a powerful long-term goal for Valneva. The company's strategic focus on specific diseases like Lyme disease and chikungunya, coupled with the progression of vaccine candidates through clinical trials to regulatory approval, indicates a realistic pathway toward this aspirational vision. For example, the Lyme disease vaccine candidate VLA15, co-developed with Pfizer, completed its primary vaccination series in Phase 3 trials in July 2024, with participants being monitored through the end of the Lyme disease season in 2025. The continued expansion of their commercial presence in key markets further supports their ambition to become a leading specialty vaccine company, reinforcing the realism of their long-term trajectory. For more details on the company's foundational principles, explore this article on the Mission, Vision & Core Values of Valneva.

Valneva PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

Valneva's core values are fundamental to its identity, shaping its operational strategies and fostering a distinct company culture. These principles guide the company's commitment to addressing global health challenges through innovative vaccine solutions.

The company's four core values are innovation, quality, integrity, and patient focus. These values collectively define Valneva's approach to vaccine development, manufacturing, and distribution, ensuring ethical practices and a strong emphasis on public health needs.

Innovation

Innovation is a primary core value for Valneva, driving its focus on developing specialized vaccines for unmet medical needs. This is evident in its robust pipeline and a significant investment of €62.8 million in research and development in 2024.

Quality

Ensuring high standards in vaccine development, manufacturing, and distribution is a critical value for Valneva. This commitment to quality is reflected in rigorous clinical trial processes and regulatory submissions, building trust in products like their Japanese encephalitis vaccine, IXIARO/JESPECT, which generated €94.1 million in sales in 2024.

Integrity

Conducting business ethically and transparently is integral to Valneva's operations. This value is demonstrated through corporate compliance frameworks and transparent reporting, including their 2024 financial statements approved in June 2025, fostering trust among all stakeholders.

Patient Focus

Prioritizing patient needs and ensuring vaccine access is a fundamental value for Valneva. This is shown by their distribution of over 5 million doses of IXIARO and over 2 million doses of DUKORAL globally in 2024, and partnerships like the $41.3 million CEPI grant in 2024 to enhance access in low- and middle-income countries. To understand more about Valneva's market position, read about the Competitors Landscape of Valneva.

These core values of Valneva SE define its strategic priorities and company culture. Understanding Valneva's mission vision and values statement is crucial to grasp how these principles influence the company's strategic decisions and future direction. Explore the next chapter to delve into how mission and vision influence the company's strategic decisions.

Valneva Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

A company's mission and vision statements serve as the bedrock for its strategic decisions, providing a clear direction for its operations and long-term aspirations. These guiding principles are crucial in shaping how a company navigates market challenges and pursues growth opportunities.

Valneva's Mission, Vision, and Strategic Alignment

Valneva's overarching vision is to contribute to a world free from vaccine-preventable diseases. This vision directly informs its integrated business model, which prioritizes the advancement of late-stage clinical programs towards regulatory approval and commercialization, aiming for first-, best-, or only-in-class status.

• Valneva's mission is to address unmet medical needs through innovative vaccine development.
• The company's vision guides its focus on diseases with significant public health impact.
• Strategic decisions are made to support the goal of being a leader in vaccine innovation.
• The business model is designed for rapid progression of promising vaccine candidates.
• Valneva's corporate purpose is to improve global health through preventative medicine.

R&D Investment Driven by Mission

Valneva's commitment to its mission is evident in its substantial R&D investments. In 2024, the company allocated €62.8 million to research and development, a figure directly tied to advancing vaccines for diseases with high unmet medical needs, such as Lyme disease and chikungunya.

Strategic Partnerships and Market Expansion

The company's market expansion and partnership strategies, exemplified by its chikungunya vaccine, directly align with its mission to improve global health access. Securing approvals in new regions and obtaining grants for broader access in low- and middle-income countries demonstrate this commitment.

Financial Prudence Supporting Strategic Goals

Valneva's financial management reflects its strategic priorities. The company has focused on reducing operating cash burn, with a significant reduction of 67% in 2024, and further in H1 2025 (from €66.3 million to €10.9 million), enabling continued strategic investments in its pipeline.

Commercial Success and Pipeline Advancement

The company's commercial execution has led to revenue growth, with total revenues increasing by 10% to €169.6 million in 2024. This financial performance supports the ongoing strategic objective of advancing its science-driven pipeline, as highlighted by the CFO in February 2025.

Valneva's Core Values in Action

While specific core values are not explicitly detailed in the provided information, the company's actions demonstrate a commitment to innovation, scientific rigor, and global health impact. These principles underpin Valneva's approach to vaccine development and commercialization.

Understanding Valneva's Strategic Priorities

Valneva's strategic priorities are clearly aligned with its mission and vision. The focus on late-stage clinical development, market access, and financial discipline ensures that resources are effectively deployed to achieve its long-term goal of contributing to a world free from vaccine-preventable diseases. For more on the company's journey, explore the Brief History of Valneva.

Valneva's mission and vision are integral to its strategic decision-making, guiding its investments in R&D and market expansion to achieve its goal of a world free from vaccine-preventable diseases. Continue reading to explore core improvements to the company's mission and vision.

Valneva Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔

Valneva's mission and vision statements are foundational to its operations, guiding its strategic direction and corporate culture. Enhancing these statements to reflect evolving industry landscapes and technological advancements can further solidify its market position.

Refining the company's strategic vision to explicitly incorporate long-term objectives, such as geographic expansion or targeted technology investments, can provide greater clarity and direction.

Emphasize Technological Innovation in Vision Statement

Valneva could strengthen its 'Innovation' value by explicitly mentioning its commitment to pioneering novel vaccine technologies and leveraging advanced platforms, signaling adaptability to industry trends.

Integrate Sustainability into Core Mission

Formally embedding sustainability into the core mission or vision, beyond its ESG classification, would demonstrate a proactive stance on climate change and its health impacts.

Clarify Long-Term Strategic Goals

Refining the strategic vision to explicitly connect it with long-term goals, such as specific market penetration targets or the development of next-generation vaccine platforms, can enhance clarity.

Connect Values to Performance Metrics

By linking core values, such as innovation and sustainability, to performance-based remuneration policies, Valneva reinforces their importance and encourages their integration into daily operations.

Valneva's mission is to contribute to global health by developing and commercializing innovative vaccines against infectious diseases. The company's vision is to be a leading biotechnology company focused on vaccines, driven by scientific excellence and a commitment to addressing unmet medical needs. Valneva's core values include innovation, integrity, collaboration, and accountability. These values underpin the company's approach to research and development, manufacturing, and commercial operations. In 2024, Valneva reported revenue of €160.6 million, with a focus on its vaccine portfolio, including its Japanese encephalitis vaccine, which is a significant contributor to its financial performance. The company’s Growth Strategy of Valneva is centered on advancing its pipeline and expanding its market reach.